Project Grant K01HL173622
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$145K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,220,472.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on using B cell therapy to ameliorate pulmonary and neurological sequelae in survivors of acute respiratory distress syndrome (ARDS). The key aims are to study the efficiency of B cell homing to the lungs and brain, identify the immunomodulatory...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $656,750 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to advance the use of Electrical Impedance Tomography (EIT) for bedside lung perfusion imaging in patients with Acute Respiratory Distress Syndrome (ARDS). The key...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $294,023 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Heartlung Corporation to develop the AUTOCHAMBER AI tool. AUTOCHAMBER is designed to opportunistically screen existing chest CT scans for early detection of enlarged cardiac chambers and left ventricular hypertrophy, which can indicate risk of atrial fibrillation, stroke, and heart failure. The project...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant will fund the development of a high-throughput platform to measure the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology will...